UnknownNot Applicable

A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)

Canada120 participantsStarted 2016-09

Plain-language summary

Background: In women with hormone receptor positive (HR+) breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage. Nonadherence is a particular challenge in older women, even though they stand to benefit the most from AET. Therefore, a novel e-health tool (OPTIMUM) that integrates real-time analysis of health administrative claims data was developed to provide point-of-care decision support for clinicians.

Who can participate

Age range65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Must be ≥ 65 years old,
✓. Have been diagnosed with incident (non-metastatic) breast cancer,
✓. Have a histologically-confirmed breast adenocarcinoma,
✓. Have undergone breast surgery for stages I-III disease,
✓. Have medical insurance with the Régie de l'Assurance Maladie du Québec (RAMQ) for at least 1 year prior to surgery,
✓. Have HR positive disease,
✓. Have no history of AET use prior to the diagnosis of breast cancer,
✓. Expected to initiate AET or have only recently initiated AET (\<6 months) but are free of previous discontinuation events,

What they're measuring

Proportion of patients discontinuing adjuvant endocrine therapy treatment

Timeframe: 1.5 years

Trial details

NCT IDNCT02876848

SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06

Contact for this trial

Ari N Meguerditchian, MD

(514) 934-1934 ari.meguerditchian@mcgill.ca

View on ClinicalTrials.gov More Breast Neoplasms trials